Browsing by Subject "Tenofovir"

Fale com a Fiocruz

Fundação Oswaldo Cruz

Now showing items 1-12 of 12

Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for hiv pre-exposure prophylaxis

Solomon, Marc M. et al. | Date Issued: 2014
Comparative effectiveness of tenofovir in HIV-infected treatment-experienced patients: systematic review and meta-analysis

Ewald, Hannah et al. | Date Issued: 2017
Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial

Mulligan, Kathleen et al. | Date Issued: 2015
Herpes Simplex Virus Type 2 Acquisition Among HIV-1-Infected Adults Treated With Tenofovir Disoproxyl Fumarate as Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study

Celum, Connie et al. | Date Issued: 2017
Herpes simplex virus type 2 acquisition among HIV-1-infected adults treated with tenofovir disoproxyl fumarate as part of combination antiretroviral therapy: results from the ACTG A5175 PEARLS study

Celum, Connie et al. | Date Issued: 2017
Kidney function in tenofovir disoproxil fumarate-based oral pre-exposure prophylaxis users: a systematic review and meta-analysis of published literature and a multi-country meta-analysis of individual participant data

Schaefer, Robin et al. | Date Issued: 2022
Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine

Glidden, David V et al. | Date Issued: 2018
Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline

Coelho, Lara Esteves et al. | Date Issued: 2019
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men

Grant, Robert M. et al. | Date Issued: 2010
Prevalence of genotypic resistance mutations in patients with chronic hepatitis B (HBV) treated with entecavir and tenofovir in two reference centers in the North and Northeast of Brazil

Pacheco, Sidelcina Rugieri et al. | Date Issued: 2023
Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis

Glidden, David V. et al. | Date Issued: 2017
Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial

Cooper, David A et al. | Date Issued: 2016